1887
  1. Home
  2. Eurosurveillance
  3. Volume 31, Issue 2, 15/Jan/2026
  4. Article
Rapid communication Open Access
Like 0
Download

SDG 3: Antimicrobial resistance

Abstract

In 2024, based on the European Committee on Antimicrobial Susceptibility Testing breakpoint, we observed a tetracycline resistance prevalence of 62.3% (2,231/3,579) in isolates from 22 European countries (range: 16.5–100%). Multivariable analysis of correlations between resistance and patients’ epidemiological characteristics found tetracycline resistance associated with men who have sex with men (aOR: 1.38; 95% CI: 1.06–1.79). Our results are important when considering measures against transmission of sexually transmitted bacterial infections in Europe, such as in the context of doxycycline post-exposure prophylaxis (doxy-PEP).

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2026.31.2.2500965
2026-01-15
2026-02-08
/content/10.2807/1560-7917.ES.2026.31.2.2500965
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/31/2/eurosurv-31-2-4.html?itemId=/content/10.2807/1560-7917.ES.2026.31.2.2500965&mimeType=html&fmt=ahah

References

  1. Molina JM, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, et al. , ANRS IPERGAY Study Group. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis. 2018;18(3):308-17.  https://doi.org/10.1016/S1473-3099(17)30725-9  PMID: 29229440 
  2. Molina JM, Bercot B, Assoumou L, Rubenstein E, Algarte-Genin M, Pialoux G, et al. , ANRS 174 DOXYVAC Study Group. Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design. Lancet Infect Dis. 2024;24(10):1093-104.  https://doi.org/10.1016/S1473-3099(24)00236-6  PMID: 38797183 
  3. Luetkemeyer AF, Donnell D, Dombrowski JC, Cohen S, Grabow C, Brown CE, et al. , DoxyPEP Study Team. Postexposure doxycycline to prevent bacterial sexually transmitted infections. N Engl J Med. 2023;388(14):1296-306.  https://doi.org/10.1056/NEJMoa2211934  PMID: 37018493 
  4. Sankaran M, Glidden DV, Kohn RP, Nguyen TQ, Bacon O, Buchbinder SP, et al. Doxycycline postexposure prophylaxis and sexually transmitted infection trends. JAMA Intern Med. 2025;185(3):266-72.  https://doi.org/10.1001/jamainternmed.2024.7178  PMID: 39761052 
  5. Jarolimova J, Bassett IV, Platt L, Germain C, Parker RA, Ard KL. Changes in clinic-level STI burden after doxycycline post-exposure prophylaxis implementation in an urban sexual health clinic. Sex Transm Dis. 2026.  https://doi.org/10.1097/OLQ.0000000000002206  PMID: 40525823 
  6. Traeger MW, Leyden WA, Volk JE, Silverberg MJ, Horberg MA, Davis TL, et al. Doxycycline postexposure prophylaxis and bacterial sexually transmitted infections among individuals using HIV preexposure prophylaxis. JAMA Intern Med. 2025;185(3):273-81.  https://doi.org/10.1001/jamainternmed.2024.7186  PMID: 39761062 
  7. Cole MJ, Quinten C, Jacobsson S, Day M, Amato-Gauci AJ, Woodford N, et al. , Euro-GASP network. The European gonococcal antimicrobial surveillance programme (Euro-GASP) appropriately reflects the antimicrobial resistance situation for Neisseria gonorrhoeae in the European Union/European Economic Area. BMC Infect Dis. 2019;19(1):1040.  https://doi.org/10.1186/s12879-019-4631-x  PMID: 31822275 
  8. The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints (v 15.0). Växjö: EUCAST; 2025. Available from: https://www.eucast.org/bacteria/clinical-breakpoints-and-interpretation/clinical-breakpoint-tables/
  9. Unemo M, Cole MJ, Kodmon C, Day M, Jacobsson S, Balla E, et al. , European Gonococcal Tetracycline-Resistance Study Group. High tetracycline resistance percentages in Neisseria gonorrhoeae in Europe: is doxycycline post-exposure prophylaxis unlikely to reduce the incident gonorrhoea cases? Lancet Reg Health Eur. 2024;38:100871.  https://doi.org/10.1016/j.lanepe.2024.100871  PMID: 38476738 
  10. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. (31st ed). CLSI supplement M100. Wayne, PA: CSLI; 2021.
  11. European Centre for Disease Prevention and Control (ECDC). Gonococcal antimicrobial susceptibility surveillance in the European Union/European Economic Area. Stockholm; ECDC; 2025 Oct 15. Available from: https://www.ecdc.europa.eu/en/publications-data/gonococcal-antimicrobial-susceptibility-surveillance
  12. Do K, Unemo M, Kenyon C, Hocking JS, Kong FYS. Tetracycline-resistant Neisseria gonorrhoeae global estimates-impacts on doxycycline post-exposure prophylaxis implementation and monitoring: a systematic review. JAC Antimicrob Resist. 2025;7(4):dlaf120.  https://doi.org/10.1093/jacamr/dlaf120  PMID: 40636396 
  13. Schröder D, Cherdtrakulkiat T, Doanh LH, Golparian D, Heng LS, Hoffman I, et al. , WHO EGASP tetracycline study group. Exceedingly high levels of tetracycline resistance in Neisseria gonorrhoeae in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021-2024-doxycycline post-exposure prophylaxis will unlikely impact gonorrhoea burdens. J Antimicrob Chemother. 2025;80(5):1291-5.  https://doi.org/10.1093/jac/dkaf066  PMID: 40099718 
  14. Soge OO, Thibault CS, Cannon CA, McLaughlin SE, Menza TW, Dombrowski JC, et al. Potential impact of doxycycline post-exposure prophylaxis on tetracycline resistance in Neisseria gonorrhoeae and colonization with tetracycline-resistant Staphylococcus aureus and group A Streptococcus. Clin Infect Dis. 2025;80(6):1188-96.  https://doi.org/10.1093/cid/ciaf089  PMID: 40036749 
  15. Berçot B, Assoumou L, Caméléna F, Voitichouk C, Mérimèche M, Ouattara M, et al. Antimicrobial drug-resistant Neisseria gonorrhoeae (GC) infections in men using doxycycline postexposure prophylaxis. A substudy of the ANRS 174 DOXYVAC trial. Clin Infect Dis. 2025;ciaf591.; Epub ahead of print.  https://doi.org/10.1093/cid/ciaf591  PMID: 41208026 
  16. Boschiero MN, Sansone NMS, Matos LR, Marson FAL. Efficacy of doxycycline as preexposure and/or postexposure prophylaxis to prevent sexually transmitted diseases: a systematic review and meta-analysis. Sex Transm Dis. 2025;52(2):65-72.  https://doi.org/10.1097/OLQ.0000000000002082  PMID: 39316078 
  17. Jo JH, Harkins CP, Schwardt NH, Portillo JA, Zimmerman MD, Carter CL, et al. , NISC Comparative Sequencing Program. Alterations of human skin microbiome and expansion of antimicrobial resistance after systemic antibiotics. Sci Transl Med. 2021;13(625):eabd8077.  https://doi.org/10.1126/scitranslmed.abd8077  PMID: 34936382 
  18. Chu VT, Glascock A, Donnell D, Grabow C, Brown CE, Ward R, et al. Impact of doxycycline post-exposure prophylaxis for sexually transmitted infections on the gut microbiome and antimicrobial resistome. Nat Med. 2025;31(1):207-17.  https://doi.org/10.1038/s41591-024-03274-2  PMID: 39363100 
  19. Kong FYS, Kenyon C, Unemo M. Important considerations regarding the widespread use of doxycycline chemoprophylaxis against sexually transmitted infections. J Antimicrob Chemother. 2023;78(7):1561-8.  https://doi.org/10.1093/jac/dkad129  PMID: 37129293 
  20. Unemo M, Kong FYS. Doxycycline-PEP - novel and promising but needs monitoring. Nat Rev Urol. 2023;20(9):522-3.  https://doi.org/10.1038/s41585-023-00788-1  PMID: 37277465 
High prevalence of tetracycline resistance in Neisseria gonorrhoeae across 22 European countries, 2024
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Susanne+Jacobsson&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Jacobsson Susanne</a>, <a href="/search?value1=Michelle+J+Cole&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Cole Michelle J</a>, <a href="/search?value1=Melissa+Jansen+van+Rensburg&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Jansen van Rensburg Melissa</a>, <a href="/search?value1=Daniel+Schr%C3%B6der&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Schröder Daniel</a>, <a href="/search?value1=Otilia+M%C3%A5rdh&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mårdh Otilia</a>, <a href="/search?value1=Csaba+K%C3%B6dm%C3%B6n&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ködmön Csaba</a>, <a href="/search?value1=Magnus+Unemo&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Unemo Magnus</a>, <a href="/search?value1=the+Euro-GASP+tetracycline+study+group&option1=author&noRedirect=true" class="nonDisambigAuthorLink">the Euro-GASP tetracycline study group</a></span>. High prevalence of tetracycline resistance in Neisseria gonorrhoeae across 22 European countries, 2024. <a href="/content/ecdc">Euro Surveill.</a> 2026;31(2):pii=2500965. <a href="https://doi.org/10.2807/1560-7917.ES.2026.31.2.2500965" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2026.31.2.2500965</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 21 Dec 2025;&nbsp;&nbsp; <span class="generated">Accepted</span>: 14 Jan 2026 </span> </p>
/content/10.2807/1560-7917.ES.2026.31.2.2500965
/content/10.2807/1560-7917.ES.2026.31.2.2500965
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error